Northwestern Medicine scientists have discovered a new biomarker to identify which patients with brain tumors called glioblastomas—the most common and malignant of primary brain tumors—might benefit from immunotherapy.
Nov 29, 2021
0
73
A high rate of genetic mutations within a tumor, known as high tumor mutation burden (TMB), was only useful for predicting clinical responses to immune checkpoint inhibitors in a subset of cancer types, according to a new ...
Mar 15, 2021
1
28
Mount Sinai researchers have made two important discoveries about the mechanism by which bladder cancer cells foil attacks from the immune system. The research, published in Cancer Cell in September, could lead to a new therapeutic ...
Sep 12, 2022
0
67
Researchers at the Icahn School of Medicine at Mount Sinai have uncovered a trio of immune cells within tumor niches that are associated with immunotherapy response in hepatocellular carcinoma (HCC). HCC is the primary type ...
Jun 15, 2023
0
21
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center sheds new light on why tumors that have spread to the brain from other parts of the body respond to immunotherapy while glioblastoma, an aggressive ...
Sep 1, 2023
0
57
In a prospective phase II study that involved patients with mismatch repair–deficient locally advanced rectal cancer, treatment with neoadjuvant single-agent, PD1 inhibitor dostarlimab resulted in a clinical complete response—as ...
Jun 9, 2022
0
72
Many breast cancers depend on hormones including estrogen or progesterone for their survival and proliferation. Eight years of lab work at the University of Colorado Cancer Center and elsewhere suggest that the androgen (AR) ...
Jun 4, 2012
0
0
Immune checkpoint blockade (ICB) inhibitors have transformed the treatment of cancer and have become the frontline therapy for a broad range of malignancies. It's because they work better than the previous standard of care.
Mar 14, 2022
0
85
Treating cancer with immunotherapies known as an immune checkpoint blockade (ICB) prior to surgery (so-called neoadjuvant immunotherapy) has been a rapidly growing area of research, but the scientific community is just scratching ...
Sep 28, 2023
0
20
China has the highest morbidity of hepatocellular carcinoma (HCC) in the world. For HCC patients in early stage disease, surgical resection is the best treatment strategy, but most patients in advanced stages lose the opportunity ...
Jun 15, 2022
0
7
